Efficacy and harms of convalescent plasma for treatment of hospitalized COVID-19 patients: a systematic review and meta-analysis
Authors:
- Alejandro PiscoyaAlejandro Piscoya
- Luis Fernando Ng-SuengLNLuis Fernando Ng-Sueng
- Angela Parra del RiegoARAngela Parra del Riego
- Renato Cerna-ViacavaRCRenato Cerna-Viacava
- Vinay PasupuletiVPVinay Pasupuleti
- Priyaleela ThotaPTPriyaleela Thota
- Yuani M RomanYRYuani M Roman
- Adrian V HernandezAdrian V Hernandez
Open Access
- 4 August 2021
- journal article
- review article
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 17 (5) , 1251-1261
Abstract
Introduction: We systematically reviewed benefits and harms of convalescent plasma (CP) in hospitalized COVID-19 patients.Material and methods: Randomized controlled trials (RCTs) and observational studies assessing CP effects on hospitalized, adult COVID-19 patients were searched until November 24, 2020. We assessed risk of bias (RoB) using Cochrane RoB 2.0 and ROBINS-I tools. Inverse variance random effect meta-analyses were performed. Quality of evidence was evaluated using GRADE methodology. Primary outcomes were all-cause mortality, clinical improvement, and adverse events.Results: Five RCTs (n = 1067) and 6 cohorts (n = 881) were included. Three and 1 RCTs had some concerns and high RoB, respectively; and there was serious RoB in all cohorts. Convalescent plasma did not reduce all-cause mortality in RCTs of severe (RR = 0.60, 95% CI: 0.33–1.10) or moderate (RR = 0.60, 95% CI: 0.09–3.86) COVID-19 vs. standard of care (SOC); CP reduced all-cause mortality vs. SOC in cohorts (RR = 0.66, 95% CI: 0.49–0.91). Convalescent plasma did not reduce invasive ventilation vs. SOC in moderate disease (RR = 0.85, 95% CI: 0.47–1.55). In comparison to placebo + SOC, CP did not affect all-cause mortality (RR = 0.75, 95% CI: 0.48–1.16) or clinical improvement (HR = 1.07, 95% CI: 0.82–1.40) in severe patients. Adverse and serious adverse events were scarce, similar between CP and controls. Quality of evidence was low or very low for most outcomes.Conclusions: In comparison to SOC or placebo + SOC, CP did not reduce all-cause mortality in RCTs of hospitalized COVID-19 patients. Convalescent plasma did not have an effect on other clinical or safety outcomes. Until now there is no good quality evidence to recommend CP for hospitalized COVID-19 patients.Keywords
This publication has 20 references indexed in Scilit:
- Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid reviewCochrane Database of Systematic Reviews, 2020
- Convalescent plasma transfusion for the treatment of COVID‐19: Systematic reviewJournal of Medical Virology, 2020
- Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019The Journal of Infectious Diseases, 2020
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences, 2020
- Statins and the COVID-19 main protease: in silico evidence on direct interactionArchives of Medical Science, 2020
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- Challenges of Convalescent Plasma Infusion Therapy in Middle East Respiratory Coronavirus Infection: A Single Centre ExperienceAntiviral Therapy, 2017
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventionsBMJ, 2016
- GRADE guidelines: 3. Rating the quality of evidenceJournal of Clinical Epidemiology, 2011
- Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus InfectionClinical Infectious Diseases, 2011